Secondary loss of response to infliximab in pediatric Crohn's disease: real-world experience in China.

ABSTRACT:

Background

Infliximab (IFX) is recognized as an effective drug for the treatment of pediatric Crohn's disease (CD), but approximately 23-60% develop secondary loss of response (LOR) to IFX. Currently, few studies have focused on the influencing factors on secondary LOR to IFX in pediatric CD patients. In this study, we aimed to analyze factors influencing the secondary LOR to IFX in pediatric CD patients.

Methods

A retrospective analysis was conducted of the clinical data for 69 CD patients treated with IFX in the department of gastroenterology of Beijing Children's Hospital between September 2015 and December 2022. Univariate analysis was conducted using the Log-rank test, and a Cox proportional hazards regression model was used to analyze the factors influencing secondary

SUBMITTER: Guan D 

PROVIDER: S-EPMC12552181 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature